Syndax Pharmaceuticals
SNDX
75 hedge funds and large institutions have $124M invested in Syndax Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 22 closing their positions.
536% more call options, than puts
Call options by funds: $4.8M | Put options by funds: $755K
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
17% more capital invested
Capital invested by funds: $106M → $124M (+$18M)
4.61% more ownership
Funds ownership: 61.05% → 65.66% (+4.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 84 → 75 (-9)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.27M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.69M |
| 3 |
Renaissance Technologies
New York
|
+$1.69M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.21M |
| 5 |
6CM
683 Capital Management
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.38M |
| 2 |
JP Morgan Chase
New York
|
-$1.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.51M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.39M |
| 5 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$929K |
SNDX Hedge Fund Activity: Q3 2018 in Review
75 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2018, worth a combined $124M — up 17% from $106M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SNDX and 13 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 28 added.
The largest buyer was Millennium Management, adding an estimated $3.27M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.38M sold.
- 75 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2018, down from 84 in Q2 2018.
- Funds reported $124M of Syndax Pharmaceuticals stock for Q3 2018, up 17% quarter-over-quarter.
- 13 funds opened new Syndax Pharmaceuticals positions in Q3 2018 and 22 closed out, a net change of -9 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2018 was Millennium Management, an estimated $3.27M added.
- The largest Syndax Pharmaceuticals seller in Q3 2018 was Alyeska Investment Group, an estimated $2.38M sold.
Based on aggregated 13F filings for Q3 2018.